COLLEGIUM PHARMACEUTICAL INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The disclosure set forth in Part II – Item 2 above is incorporated herein by reference.
The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted, amended, or terminated by our directors and officers during the three months ended September 30, 2024:
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · Trading Arrangement · · · · | ||||||||||||||
| Name | | Title | | Action | | Effective Date | | Rule 10b5-1 | | Non-Rule 10b5-1 | | Scheduled Expiration Date of Trading Plan (1) | | Maximum Shares Subject to Trading Plan |
| Colleen Tupper | | Executive Vice President and Chief Finance Officer | | Adoption | | August 14, 2024 | | X | | | | April 30, 2025 | | 69,260 |
| Scott Dreyer | | Executive Vice President and Chief Commercial Officer | | Adoption | | August 28, 2024 | | X | | | | August 22, 2025 | | 106,450 |
| Shirley Kuhlmann | | Executive Vice President, Chief Administrative Officer, General Counsel & Secretary | | Adoption | | September 13, 2024 | | X | | | | March 31, 2025 | | 107,500 |
| (1) | A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.